Di Ianni, Tommaso http://orcid.org/0000-0001-8305-8205
Ewbank, Sedona N. http://orcid.org/0000-0002-6985-1431
Levinstein, Marjorie R. http://orcid.org/0000-0003-4360-1503
Azadian, Matine M. http://orcid.org/0000-0002-8253-7113
Budinich, Reece C.
Michaelides, Michael http://orcid.org/0000-0003-0398-4917
Airan, Raag D. http://orcid.org/0000-0001-5259-5606
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (RF1MH114252, UG3NS115637)
Ford Foundation (Ford Foundation Fellowship)
NSF | Directorate for Education and Human Resources (Graduate Research Fellowship)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (ZIA000069)
Article History
Received: 23 April 2023
Accepted: 17 January 2024
First Online: 30 January 2024
Competing interests
: R.D.A. has equity and has received equity/stock options and consulting fees from Cordance Medical and Lumos Labs and grant funding from AbbVie Inc. M.M. has received research funding from AstraZeneca, Redpin Therapeutics, and Attune Neurosciences, Inc. T.D.I. has equity/stock options and received consulting fees from Attune Neurosciences, Inc. All other authors declare no conflicts of interest.